Response to CAR T cell therapy can be explained by ecological cell dynamics and stochastic extinction eventsdoi:10.1101/717074Gregory J. KimmelFrederick L. LockePhilipp M. AltrockCold Spring Harbor Laboratory
Cancer immunotherapy has become a major treatment option in recent years. One of the most promising approaches is Chimeric antigen receptor (CAR)-T cell therapy, which involves engineering T cells to target specific cancer cells. However, CAR-T cell therapy can also have some adverse side effects...
In recent decades, the advent of immune-based therapies, most notably Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of numerous studies indicate that CAR-T cell therapy has had a remarkable ability and successful performance in treating blood...
CAR-T therapy is available for children with B-cell acute lymphoblastic leukemia when first-line systemic chemotherapy fails, relapses after hematopoietic stem cell transplantation, or second and subsequent relapse. It can significantly reduce the risk of relapse in children with leukemia who have expe...
“With CAR T-cell therapy, I think we need to be smarter about looking for persistence of the CAR or surrogates of persistence of CAR,” explained Kebriaei, a stem cell transplant physician at The University of Texas MD Anderson Cancer Center. “In the group that appears to have persi...
car-t therapy. only one such case tested positive, the researchers reported. according to rejeski, it's also possible that car-t therapies are a victim of their own success: patients are now living longer thanks to the treatments, giving new cancers more years in which...
As an “off-the-shelf” therapy, P-BCMA-ALLO1 could provide a novel therapeutic avenue to treat patients with rapidly progressing multiple myeloma who are ineligible for autologous therapies, Dholaria explained. He added that, “In United States, we are now in a post-BCMA era when i...
Treatment decisions in mantle cell lymphoma (MCL) have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel (Tecartus) in the relapsed/refractory setting, explained Alan P. Z. Skarbnik, MD. Previously, the treatment of choice for patients who recurr...
To overcome the limitations of CAR T cell therapy, Álvarez-Vallina, Laura Díez-Alonso, PhD, also at the at the Cancer Immunotherapy Unit (UNICA), Department of Immunology Hospital Universitario 12 de Octubre, and colleagues constructed an alternative T cell therapy design based on STAb-T...
Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system. This promising treatment comes at a cost, however: The manufacturers charge u